Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Solesence (SLSN) Research & Development (2016 - 2026)

Solesence filings provide 17 years of Research & Development readings, the most recent being $1.0 million for Q1 2026.

  • On a quarterly basis, Research & Development rose 2.36% to $1.0 million in Q1 2026 year-over-year; TTM through Mar 2026 was $4.1 million, a 4.34% increase, with the full-year FY2025 number at $4.1 million, up 6.59% from a year prior.
  • Research & Development hit $1.0 million in Q1 2026 for Solesence, up from $1.0 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $1.1 million in Q4 2024 to a low of $666000.0 in Q1 2022.
  • Median Research & Development over the past 5 years was $970000.0 (2024), compared with a mean of $931823.5.
  • Biggest five-year swings in Research & Development: soared 50.6% in 2023 and later fell 12.82% in 2024.
  • Solesence's Research & Development stood at $727000.0 in 2022, then grew by 7.98% to $785000.0 in 2023, then skyrocketed by 38.98% to $1.1 million in 2024, then dropped by 5.13% to $1.0 million in 2025, then increased by 0.68% to $1.0 million in 2026.
  • The last three reported values for Research & Development were $1.0 million (Q1 2026), $1.0 million (Q4 2025), and $1.1 million (Q3 2025) per Business Quant data.